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MiR30-GALNT1/2 Axis-Mediated Glycosylation Contributes to the
Increased Secretion of Inactive Human Prohormone for Brain
Natriuretic Peptide (proBNP) From Failing Hearts
Yasuaki Nakagawa, MD, PhD; Toshio Nishikimi, MD, PhD; Koichiro Kuwahara, MD, PhD;* Aoi Fujishima, BS; Shogo Oka, PhD; Takayoshi
Tsutamoto, MD, PhD; Hideyuki Kinoshita, MD, PhD; Kazuhiro Nakao, MD; Kosai Cho, MD; Hideaki Inazumi, MD; Hiroyuki Okamoto, PhD;
Motohiro Nishida, PhD; Takao Kato, MD, PhD; Hiroyuki Fukushima, MS; Jun K. Yamashita, MD, PhD; Wino J. Wijnen, PhD; Esther E.
Creemers, PhD; Kenji Kangawa, PhD; Naoto Minamino, PhD; Kazuwa Nakao, MD, PhD; Takeshi Kimura, MD, PhD
Background-—Recent studies have shown that plasma levels of the biologically inactive prohormone for brain natriuretic peptide
(proBNP) are increased in patients with heart failure. This can contribute to a reduction in the effectiveness of circulating BNP and
exacerbate heart failure progression. The precise mechanisms governing the increase in proBNP remain unclear, however.
Methods and Results-—We used our recently developed, highly sensitive human proBNP assay system to investigate the
mechanisms underlying the increase in plasma proBNP levels. We divided 53 consecutive patients hospitalized with heart failure
into 2 groups based on their aortic plasma levels of immunoreactive BNP. Patients with higher levels exhibited more severe heart
failure, a higher proportion of proBNP among the immunoreactive BNP forms secreted from failing hearts, and a weaker effect of
BNP as estimated from the ratio of plasma cyclic guanosine monophosphate levels to log-transformed plasma BNP levels.
Glycosylation at threonines 48 and 71 of human proBNP contributed to the increased secretion of proBNP by attenuating its
processing, and GalNAc-transferase (GALNT) 1 and 2 mediated the glycosylation-regulated increase in cardiac human proBNP
secretion. Cardiac GALNT1 and 2 expression was suppressed by microRNA (miR)-30, which is abundantly expressed in the
myocardium of healthy hearts, but is suppressed in failing hearts.
Conclusions-—We have elucidated a novel miR-30-GALNT1/2 axis whose dysregulation increases the proportion of inactive
proBNP secreted by the heart and impairs the compensatory actions of BNP during the progression of heart failure. ( J Am Heart
Assoc. 2017;6:e003601. DOI: 10.1161/JAHA.116.003601.)
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A lthough originally isolated from the porcine brain, B-typeor brain natriuretic peptide (BNP) is a cardiac hormone
mainly produced and secreted by the ventricles.1,2 Several
pathological stimuli induce expression of a BNP precursor,
preproBNP, in cardiac myocytes.3,4 Removing the signal
peptide from preproBNP yields the BNP prohormone proBNP,
which is in turn cleaved intracellularly to form the biologically
active mature BNP (BNP-32) and inactive N-terminal proBNP
(NT-proBNP) prior to their secretion (Figure 1A).4 Plasma
levels of both BNP and NT-proBNP are elevated in patients
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Figure 1. Cardiac secretion of prohormone for brain natriuretic peptide (proBNP) is increased in patients with heart failure.
A, Schematic representation of proBNP processing and secretion by cardiac myocytes. Conventional BNP assays measure
both human proBNP and mature BNP (dashed box). B through D, Plasma levels of BNP (B), proBNP (C), and estimated BNP-32
(D) in coronary sinus (CS) and aortic root (AO) of each individual (n=53). *P<0.05 using paired t test. E and F, proBNP/BNP
ratios in the CS (E) and the ΔproBNPCSAO/ΔBNPCSAO ratio (F) in heart failure patients with high (n=27) or low BNP (n=26).
*P<0.05 using unpaired t test. G, Cardiac index in heart failure patients with a high (n=27) or low proBNP/BNP ratio (n=26).
Data are shown as dot plots with meansSEM. *P<0.05 using unpaired t test.
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with cardiac hypertrophy or heart failure, and are currently
established biomarkers whose levels correlate well with the
prognosis and severity of heart failure.5,6
Recent studies have shown that unprocessed proBNP also
circulates in healthy individuals, and that its plasma levels are
elevated in patients with severe heart failure.7,8 This is
noteworthy because the immunoassay system currently used
to measure human BNP levels detects both proBNP and
mature BNP (Figure 1A).4,9 Furthermore, recent in vitro
studies have shown that proBNP has much less ability to
stimulate cyclic guanosine monophosphate (cGMP) synthesis
in vascular smooth muscle and endothelial cells than mature
BNP.10 Consequently, increases in the proportion of proBNP
among the total secreted BNP forms, which include both
proBNP and mature BNP, can lead to a reduction in the
effectiveness of circulating BNP and the progression of heart
failure. Indeed, the paradox in patients with severe heart
failure is that the biological activity of BNP is attenuated,
despite high circulating levels.11,12 The mechanisms govern-
ing the cardiac secretion and peripheral metabolism of
proBNP in heart failure patients have not been fully
elucidated, however.
Within the Golgi apparatus of ventricular myocytes, human
proBNP is post-translationally glycosylated to various degrees
at 7 sites in its N-terminal region: threonine (Thr)36, serine
(Ser)37, Ser44, Thr48, Ser53, Thr58, and Thr71.13 The O-
glycosylated proBNP is then transported to the trans-Golgi
network, where it is cleaved into mature BNP and NT-proBNP,
presumably by the proteolytic enzyme furin,9 after which
these products are secreted into the circulation. Recently,
Semenov et al reported that O-glycosylation at Thr71 inhibits
the processing of recombinant human proBNP in HEK293
cells.14 On the other hand, Peng et al reported that wild-type
(WT)-proBNP and a mutant proBNP in which Thr71 was
substituted to alanine (Ala) were processed similarly in HL-1
cells.15 Thus, the signiﬁcance of O-glycosylation in the N-
terminal region of human proBNP to its processing and
secretion remained unclear. Importantly, most of the glyco-
sylation sites on human proBNP are not conserved in rodent
proBNP. In rats, nearly all circulating BNP is mature BNP-45,
irrespective of the presence or absence of heart failure.16
In the present study, we used our recently developed, highly
sensitive and selective assay system for human proBNP to
investigate the cardiac production and peripheral metabolism
of proBNP in patients with heart failure. Cardiac production of
proBNP and the proportion of proBNP among secreted BNP
forms are both increased in accordance with the severity of
heart failure. We found that 2 O-glycosylation sites in human
proBNP, Thr48 and Thr71, act cooperatively to inhibit the
processing of proBNP, thereby increasing proBNP secretion by
cardiac myocytes. Furthermore, we show that microRNA-30-
mediated regulation of N-acetylgalactosaminyltransferase
(GalNac-T; GALNT) 1 and 2 expression modulates the glycosy-




Blood was sampled from the coronary sinus (CS) and aortic
root (AO) during cardiac catheterization in 53 consecutive
patients hospitalized with heart failure at the Shiga Univer-
sity of Medical Science Hospital between 2003 and 2010
(study 1).11 The patients’ clinical characteristics are sum-
marized in Table 1. We divided this study population into 2
groups based on median BNP level in the AO (high BNP
group had BNP >22.3 pmol/L; low BNP group had BNP
≤22.3 pmol/L) to compare the proBNP/BNP ratios between
these 2 groups. For the experiments measuring plasma
proBNP and BNP levels in a peripheral vein and artery,
venous blood was sampled from the superior vena cava or
femoral vein and arterial blood was sampled from the cubital
or femoral artery, respectively, of 25 consecutive patients
hospitalized with heart failure at Kyoto University Hospital
between 2011 and 2012 (study 2). The clinical character-
istics of these patients are summarized in Table 2. Ethical
approval was granted by the Kyoto University Hospital
Ethical Committee and the Committee on Human Investiga-
tion at Shiga University of Medical Science. The aims of the
study were explained to each participant, and written
informed consent was obtained. All clinical investigations
were conducted according to the principles expressed in the
Declaration of Helsinki.
Measurement of BNP and proBNP
We measured concentrations of both proBNP and BNP in
plasma or conditioned medium using our recently developed,
highly sensitive immunochemiluminescent assay for proBNP
(Shionogi & Co. Ltd, Osaka, Japan) and the conventional
immunochemiluminescent assay for BNP (Shionogi & Co. Ltd),
respectively. In both assays, an antibody recognizing a
common epitope in the C-terminal regions of proBNP and
BNP was used as the capture antibody. An antibody recognizing
an epitope in the N-terminal portion of proBNP was used as the
signal antibody in the proBNP assay, while an antibody
recognizing an epitope in the ring structure of BNP was used
as the signal antibody in the conventional BNP assay.
Importantly, because the afﬁnities of the 2 signal antibodies
were the same, we were able to accurately measure the
proBNP/proBNP ratio in plasma or conditioned medium as an
index of the proBNP processing efﬁciency. We previously
addressed this issue in detail.7 Both assays are speciﬁc for
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human BNP and proBNP, and do not cross-react to rat BNP-45
or rat proBNP-95. It this study, we use the term “BNP” to refer
to immunoreactive BNP measured in the assay system using
the same set of antibodies used in the conventional BNP assay
system (Shionogi & Co., Ltd). Thus, immunoreactive BNP
consists of both unprocessed proBNP and processed mature
BNP. Estimated mature BNP was then calculated using the
following formula: estimated mature BNP=BNPproBNP. The
transcardiac proBNP gradient (ΔproBNPCSAO) was calculated
as proBNP in the CS minus proBNP in the AO.
Animal Experiments
The animal care and all experimental protocols were reviewed
and approved by the Animal Research Committee at Kyoto
University Graduate School of Medicine and University of
Amsterdam, and conformed to the US National Institute of
Health Guide for the Care and Use of Laboratory Animals.
Inbred male Dahl salt-sensitive (DS) rats (Japan SLC, Hama-
matsu, Shizuoka, Japan) were fed a 0.3% NaCl (low salt: LS)
diet until the age of 6 weeks, after which they were fed an 8%
NaCl diet (high salt: HS).17,18 As we reported previously, DS
rats fed a high-salt diet (HS) developed hypertension and
showed concentric left ventricular hypertrophy at 11 weeks
of age.17,18 At around 17 weeks of age, the DS rats fed a HS
diet showed signs of congestive heart failure and showed
decreased fractional shortening. DS rats fed a LS diet were
Table 2. Clinical Characteristics of Patients With Heart












Pulmonary hypertension 3 (12.0%)
HR, beats/min 71.33.3
SBP, mm Hg 121.13.2
DBP, mm Hg 68.12.9
PCWP, mm Hg 11.40.8
mPAP, mm Hg 19.01.0
eGFR, mL/min 47.84.3
Serum creatinine, g/dL 1.70.4
GOT, IU/L 23.62.7
GPT, IU/L 19.32.3
DBP indicates diastolic blood pressure; DCM, dilated cardiomyopathy; eGFR, estimated
glomerular ﬁltration rate; GOT, glutamate oxaloacetate transaminase; GPT, glutamate
pyruvate transaminase; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart
disease; HR, heart rate; IHD, ischemic heart disease; mPAP, mean pulmonary artery
pressure; PCWP, pulmonary capillary wedge pressure; SBP, systolic blood pressure.
Table 1. Clinical Characteristics and Plasma proBNP and
BNP Levels in Heart Failure Patients With High or Low Aortic





Age, y 60.02.3 69.51.8 0.0022
Height, cm 165.51.2 160.81.7 0.0279
Weight, kg 67.22.5 62.30.5 0.1542
Sex, M/F 24/3 21/5 0.4091
Etiology
IHD/non IHD 17/10 14/12 0.5007
HR, beats/min 69.42.9 70.43.5 0.6724
SBP, mm Hg 124.14.4 132.13.9 0.6764
DBP, mm Hg 69.42.1 69.83.2 0.8178
MBP, mm Hg 88.92.6 95.63.1 0.7342
Serum creatinine, mg/dL 0.930.03 1.450.21 0.0734
Plasma cGMP, nmol/L 5.580.20 9.510.17 0.0008
Swan-Ganz data
CO, L/min 5.30.2 4.00.2 0.0110
PCWP, mm Hg 8.20.8 13.91.6 0.0148
Mean PAP, mm Hg 13.40.9 21.22.0 0.0030
LVEF, % 44.62.6 37.21.2 0.2030
Ao level
BNP, pmol/L 7.81.2 61.38.4 <0.0001
proBNP, pmol/L 4.70.8 36.2.4.4 <0.0001
Estimated BNP-32, pmol/L 3.10.5 25.14.4 <0.0001
CS level
BNP, pmol/L 24.53.4 137.64.5 <0.0001
proBNP, pmol/L 8.81.4 57.26.7 <0.0001
Estimated BNP-32, pmol/L 15.82.1 80.49.0 <0.0001
CSAo level
BNP, pmol/L 16.82.5 76.38.0 <0.0001
proBNP, pmol/L 4.10.8 21.03.2 <0.0001
Estimated BNP-32, pmol/L 12.71.8 55.36.2 <0.0001
Unpaired t test was used for the analysis. P<0.05 is considered signiﬁcant. Ao indicates
aortic root; BNP, brain natriuretic peptide; cGMP, cyclic guanosine monophosphate; CO,
cardiac output; CS, coronary sinus; DBP, diastolic blood pressure; HR, heart rate; IHD,
ischemic heart disease; LVEF, left ventricular ejection fraction; MBP, mean blood
pressure; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure;
proBNP, prohormone for brain natriuretic peptide; SBP, systolic blood pressure.
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used as controls. For in vivo miR-30 inhibition we used
9-week-old C57BL/6J mice, injected subcutaneously with
5 mg/kg LNA based antimiR-30c (Ribotask) or negative
control antimiR (Ribotask) at 2 different timepoints (day 0
and day 7). Mice were euthanized 4 weeks later, and hearts
were snap-frozen in liquid nitrogen for protein analysis as
previously reported.19
Hemodynamics and Cardiac Echocardiography in
DS Rats
Heart rate and blood pressure in DS rats were determined
using the tail-cuff method with a noninvasive automated
blood pressure apparatus (Softron BP-98A, Softron Co. Ltd,
Tokyo, Japan) without anesthesia. Transthoracic echocardio-
graphy was performed as previously reported.17,20 Prior to
being euthanized at 15 to 17 weeks of age, rats were
anesthetized brieﬂy with inhaled diethyl ether (Wako Pure
Chemical Industries, Osaka, Japan), and transthoracic
echocardiography was performed using a Sonos-5500
echocardiograph (Agilent Technologies, Santa Clara, CA)
equipped with a 15-MHz linear transducer. Intraventricular
septal thickness, left ventricular dimension during diastole,
and left ventricular dimension during systole were measured
using M-mode echocardiography, and percent fractioning
shortening was calculated.
Tissue Sampling From DS Rats
To obtain heart tissues from DS rats for biochemical analyses,
17-week-old LS (n=17), and HS (n=14) rats were anesthetized
with 3.0% of isoﬂurane and euthanized by decapitation
without fasting. Hearts were rapidly snap-frozen in liquid
nitrogen and stored at 80°C.
Cell Culture
Primary neonatal (2- to 4-day-old) rat ventricular myocytes
(NRVMs) and cardiac ﬁbroblasts were prepared on a Percoll
gradient as described previously and plated in gelatin-coated
24-well dishes and incubated in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% FCS.3
A human induced pluripotent stem cell line (36B3) induced
using episomal plasmid vectors encoding 6 factors (Oct3/4,
Sox2, Klf4, L-Myc, LIN28, and Glis1) was established as
previously reported.21 Cardiomyocyte differentiation was
induced using 836B3 as previously reported.22,23 Derived
cardiomyocytes were plated to a density of 59104 cells/well
in gelatin-coated 24-well dishes for proBNP/BNP measure-
ment, and at 59105 cells/dish in gelatin-coated 6-cm dishes
for protein extract.
Determination of Intracellular cGMP
Accumulation and Plasma cGMP Levels
Cells in serum-free medium were preincubated for 1 hour in
0.1 mmol/L 3-isobutyl-1-methylxanthine and then treated for
10 minutes with 10 nmol/L human BNP, human glycosylated
proBNP, or human nonglycosylated proBNP. The cells were
then lysed in 0.1 mol/L HCl at room temperature for
20 minutes, after which the lysates were centrifuged at
600g, and the cGMP levels in the supernatant were measured
using a radioimmunoassay kit (Yamasa Shoyu, Chiba, Japan).
Plasma cGMP levels were determined in blood samples
obtained from peripheral veins during cardiac catheterization
in 53 consecutive patients hospitalized with heart failure at
the Shiga University of Medical Science Hospital (study 1) by
using the radioimmunoassay kit (Yamasa Shoyu).
Plasmids
cDNA encoding full-length human pre-proBNP was ampliﬁed
by polymerase chain reaction (PCR) using a human cDNA
library as a template and cloned into pBluescript II SK(+)
(Agilent Technologies, Santa Clara, CA). After conﬁrming its
sequence, cDNA encoding human pre-proBNP (WT) was
introduced into pLVSIN-CVM Neo vector, which is a SIN-type
lentiviral vector plasmid. Human proBNP is reportedly O-
glycosylated at Thr36, Ser37, Ser44, Thr48, Ser53, Thr58, and
Thr71 in its N-terminal region. To assess the function of the O-
glycosylation of human proBNP, we generated the following
set of human proBNP mutants in which various combinations
of glycosylation sites were replaced with alanine: non-glyco,
all 7 O-glycosylation sites were substituted with Ala; T71A,
Thr71 was substituted to Ala; T48A, Thr48 was substituted
with Ala; T48A/T71A, Thr48 and Thr71 were substituted with
Ala; T58glyco, all O-glycosylation sites other than Thr58 were
substituted with Ala; S53glyco, all O-glycosylation sites
except Ser63 were substituted with Ala; T58glyco, all O-
glycosylation sites except Thr58 were substituted with Ala;
S53 glyco, all O-glycosylation sites except Ser53 were
substituted with Ala; T48glyco, all O-glycosylation sites except
Thr48 were substituted with Ala; S44glyco, all O-glycosylation
sites except Ser44 were substituted with Ala; S37glyco, all O-
glycosylation sites except Ser37 were substituted with Ala;
T36glyco, all O-glycosylation sites except Thr36 were substi-
tuted with Ala; T48/T71glyco, the 5 O-glycosylation sites
other than Thr48 and Thr 71 were substituted with Ala; S53/
T71glyco, the 5 O-glycosylation sites other than Ser53 and
Thr 71 were substituted with Ala. These mutants were
constructed using QuikChange Lightning Site-Directed Muta-
genesis Kits (Agilent Technologies) with human pre-proBNP
gene cloned into pBluescript II as the template. The
sequences of the constructs were veriﬁed by DNA
DOI: 10.1161/JAHA.116.003601 Journal of the American Heart Association 5























sequencing. The mutant genes were then introduced into
pLVSIN-CVM Neo vector for lentivirus production.
GALNT1 30untranslated region (UTR)-luc and GALNT2
30UTR-luc were generated by inserting GALNT1 30UTR or
GALNT2 30UTR containing miR-30 target sequences down-
stream of a gene encoding luciferase in the pMIR-REPORTER
kit miRNA reporter expression vector (Thermo Fisher Scien-
tiﬁc, Waltham, MA). The GALNT1 or -2 30UTR was obtained by
PCR using a human BAC clone as a template with the
following primers: GALNT1 30UTR, 50- CCC TCA GAC TAG TGA
CCA AAT TTA CAA AAA AAC G -30(forward) and 50- CAG CAC
CAA GCT TCT GAA TCT GGT TCC AG -30(reverse); GALNT-2
30UTR, 50- CTA TCA TAC TAG TGC AGG CCA GAG CAG -30
(forward) and 50- CAT CAT CAA GCT TCG GCA CGC TTT GCT C
-30 (reverse). Mutant GALNT1 30UTR-luc and mutant GALNT2
30UTR-luc, in which the miR-30 target sequences were
mutated, were obtained through site-directed mutagenesis
using GALNT1 30UTR-luc or GALNT2 30UTR-luc as the
template with the following primers: GALNT 1 miR-30 mut,
50- GAG ACT GTG CAC ACT GAT GAT ATC AAG ATT GAA AGA
GTC TTT C -30; GALNT 2 miR-30 mut, 50-CTT TGC GGT GAG
CTA TGA TAT CAT GAC ACA GTG TGC CAA AG -30.
Lentiviral Vector Production and Gene Transfer
HIV-based lentiviral vectors were generated using a Lenti-XTM
HTX Ecotropic packaging system (Takara Bio Inc., Otsu, Japan)
according to manufacturer’s guidelines with WT and mutant
human pre-proBNP gene contained in pLVSIN-CMV Neo
vectors as mentioned above. NRVMs or cardiac ﬁbroblasts
were infected with each lentivirus for 24 hours after plating,
after which the medium was exchanged. The culture medium
was collected 96 hours after the infection.
Gel Filtration Chromatography
Culture medium was extracted using Sep-Pak C18 cartridges
(Waters, Milford, MA) as previously reported,7 and the eluate
was lyophilized and dissolved in 30% acetonitrile containing
0.1% TFA. The proteins in the solution were then separated
using gel ﬁltration high-performance liquid chromatography
on a TSK gel G2000SWXL column (7.83300 mm; Tosoh Co.,
Tokyo, Japan), as previously reported.7 The column efﬂuent
was fractionated every minute, and each fraction was
analyzed using BNP and proBNP immunochemiluminescent
assays as previously described.7
Quantitative Real-Time-PCR Analysis
Using 50 ng of total RNA prepared from NRVMs or ventricles
(apical halves of hearts) with Sepasol-RNA I (Nakarai, Tesque,
Inc, Kyoto, Japan), levels of mRNA encoding rat GALNT1, 2, 3,
7, 10, 11, 12, and 15 were determined using quantitative real-
time PCR according to the manufacturer’s protocol (Applied
Biosystems Inc, Foster City, CA). Relative mRNA levels were
determined by normalization to the level of GAPDH mRNA.
The relative mRNA levels in untreated WT samples were
assigned a value of 1.0. Levels of miR-30a, b, c, d and e
expression were determined using a Taqman MicroRNA RT kit,
Taqman miRNA assay mix, and Taqman Universal PCR Master
Mix II according to the manufacturer’s protocol (Thermo
Fisher Scientiﬁc). Relative miR-30 levels were determined by
normalization to the level of U6. The relative miR-30 levels in
the controls were assigned a value of 1.0. Taqman primers
and probes for rat and mouse GALNTs, GAPDH, 18S, miR-30a,
b, c, d, e and U6 were purchased from Applied Biosystems.
Western Blot Analysis
Details of the methods used to prepare lysates from rat
ventricles were described previously.3 Brieﬂy, samples were
homogenized and sonicated in lysis buffer containing
20 mmol/L Tris-HCl (pH7.5), 150 mmol/L NaCl, 1 mmol/L
Na2EDTA, 1 mmol/L EGTA, 1% Triton, 2.5 mmol/L sodium
pyrophosphate, 1 mmol/L b-glycerophosphate, 1 mmol/L
Na3VO4, 1 lg/mL leupeptin, and 1 mmol/L phenylmethyl-
sulfonyl ﬂuoride (Cell Signaling Technology, Inc, Danvers, MA).
After the debris was cleared by centrifugation, the protein
concentration in the supernatant was quantiﬁed as the crude
extract. Extracts containing 50 lg of protein were separated
by SDS-PAGE using 10% polyacrylamide gels and then
analyzed by Western blotting using anti-GALNT1 (sc-68492;
1:1000; Santa Cruz Biotechnology Inc, Dallas, TX), anti-
GALNT2 (#104070; 1:1000; GeneTex Inc, Irvine, CA), or anti-
GAPDH (AB2302; 1:1000; Merck Millipore, Darmstadt, Ger-
many) antibody.
siRNA and miR-30c Mimic and Inhibitor
We purchased the following predesigned or designed siRNAs
(Mission siRNA) from Sigma Aldrich (St. Louis, MO): siGALNT1
(SASI_Rn01_00031243), siGALNT2 (SASI_Rn02_00216578),
siGALNT3 (SASI_Rn01_00120276), siGALNT7 (SASI_Rn01_
00030444), siGALNT10 (SASI_Rn01_00054909), siGALNT11
(SASI_Rn01_00032481), siGALNT12 (SASI_Rn02_00317391),
and GALNT15 (sense: CUG AUC AUC CAC GUU CUA UdTdT,
antisense: AUA GAA CGU GGA UGA UCA GdTdT). The siRNAs
were transfected into NRVMs using Lipofectamine RNAiMAX
transfection reagent (Thermo Fisher Scientiﬁc) according to the
manufacturer’s instructions.
We purchased the following predesigned miR-30c mimic
and inhibitor and their controls from GE Healthcare Bio-
Sciences (Pittsburgh, PA): miRIDIAN microRNA rno-miR-30c-
5p hairpin inhibitor (IH-320323-05), miRIDIAN microRNA rno-
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miR-30c-5p mimic (C-320323-03), miRIDIAN microRNA Mimic
Negative Control (CN-001000-01), and miRIDIAN microRNA
Hairpin Inhibitor Negative Control (IN-001005-01).
Statistical Analysis
Continuous variables are expressed as meanSE. The
categorical data are summarized with percentages. Unpaired
t tests were used for comparisons between 2 independent
groups, while paired t tests were used for comparisons
between 2 groups that were correlated. One-way ANOVA with
post hoc Fisher’s tests was used for comparisons among
more than 2 groups and 2-way ANOVA with post hoc Fisher’s
tests was used for comparison among 4 or 6 groups
containing 2 variables. Pearson’s correlation coefﬁcient (r)
was used for the analysis of relationship between the
proBNP/BNP ratios in veins and arteries of individual patients.
Values of P<0.05 were considered signiﬁcant.
Results
Increased Secretion of proBNP From Failing
Hearts
To conﬁrm that proBNP is secreted from failing hearts along
with mature BNP, we measured proBNP and BNP levels in
plasma collected from the AO and CS of 53 consecutive
patients hospitalized with heart failure (study 1, Table 1).
Measurements were made using both our newly developed
human proBNP-speciﬁc immunoassay system and the con-
ventional human BNP assay system, which detects both
proBNP and mature BNP (Figure 1A).7 We also estimated
mature BNP levels by subtracting the values for proBNP from
the total BNP. We found that levels of BNP, proBNP, and
estimated mature BNP were all signiﬁcantly higher in the CS
than AO (Figure 1B through 1D). The average proBNP-to-BNP
ratio (proBNP/BNP), which indicates the proportion of proBNP
among immunoreactive BNP forms in the CS, was 0.390.11
among the entire patient sample. When we divided our study
population into 2 groups based on the median BNP level in the
AO (high-BNP group, BNP >22.3 pmol/L; low-BNP group, BNP
≤22.3 pmol/L), we found that the high-BNP group exhibited
more severe heart failure than the low-BNP group (Table 1). In
addition, levels of both proBNP and estimated mature BNP
were signiﬁcantly higher in the CS and AO in high-BNP group
than the low-BNP group. The transcardiac gradient of proBNP
(ΔproBNPCSAO), which is an index of cardiac proBNP
secretion, was also signiﬁcantly higher in high-BNP than
low-BNP patients (Table 1), as were the proBNP/BNP ratio in
the CS and the ΔproBNPCSAO/ΔBNPCSAO ratio (Figure 1E
and 1F). These results indicate that proBNP is secreted from
failing hearts, and the proportion of proBNP among the
secreted BNP forms increases with increases in the severity
of heart failure.
Consistent with this ﬁnding, when we divided our study
population into 2 groups based on the median proBNP/BNP
ratio in the CS and evaluated the relationship between clinical
parameters and the proBNP/BNP ratio, we found that the
proBNP/BNP ratio correlates negatively with the cardiac
index (Figure 1G).
Peripheral Metabolism of proBNP and BNP in
Heart Failure Patients
We next measured plasma proBNP and BNP levels in a
peripheral vein and artery in 25 consecutive patients hospi-
talized with heart failure (study 2, Table 2). Venous BNP and
estimated mature BNP levels were signiﬁcantly lower than the
arterial levels, but proBNP levels did not signiﬁcantly differ
between veins and arteries (Figure 2A through 2C). Further-
more, while the proBNP/BNP ratios in the veins correlated
with the arterial ratios for the group (Figure 2D), within each
individual the venous proBNP/BNP ratio was signiﬁcantly
higher than the arterial ratio (Figure 2E). This suggests
proBNP has weaker afﬁnity for its receptors and/or less
susceptibility to degradation by peptidases (eg, neprilysin)
than mature BNP in peripheral tissues. Indeed, the ability of
glycosylated or nonglycosylated proBNP to stimulate cGMP
production was much less than that of mature BNP in both
cardiac myocytes and cardiac ﬁbroblasts (Figure 2F and 2G).
Consistent with these results, in 53 heart failure patients
studied above (study 1), the venous plasma cGMP levels-to-
logBNPAO ratios were signiﬁcantly lower in the high-BNP
group than the low-BNP group (Figure 2H).
Two Glycosylation Sites, Thr48 and Thr71, Act
Cooperatively to Attenuate proBNP Processing in
Cardiac Myocytes
To further clarify the molecular mechanisms regulating human
proBNP secretion from cardiac myocytes, we next infected
cultured primary NRVMs with a lentivirus harboring human
WT-proBNP gene and measured human proBNP and BNP
secreted into the conditioned medium.7 Although absolute
values of BNP and proBNP levels varied (Figure 3A and 3B),
proBNP/BNP ratios remained nearly constant across exper-
iments (Figure 3C). Moreover, the proBNP/BNP ratio in
medium conditioned by NRVMs expressing human proBNP
(0.360.03) was similar to the ratio in plasma samples from
the CS of heart failure patients (0.390.11) and in the
medium conditioned by human iPS-derived cardiomyocytes
(iPS-CMs) (0.380.02) (Figure 3D). With iPS-CMs, although
absolute values of BNP and proBNP levels varied (Figure 3E
and 3F), proBNP/BNP ratios remained nearly constant across
DOI: 10.1161/JAHA.116.003601 Journal of the American Heart Association 7























experiments (Figure 3G), as was observed with NRVMs. These
results indicate that NRVMs infected with a lentivirus
harboring human proBNP recapitulate the production and
secretion of proBNP and mature BNP by human cardiac
myocytes.
We then sought to determine the impact of glycosylation in
the N-terminal region of proBNP on its processing in ventricular
myocytes. We infected NRVMs with lentiviruses harboring
human WT-proBNP or 1 of several proBNP mutants in which 1
or more of the 7 glycosylated residues were replaced with
alanine (Ala) (Figure 4A and 4B). In medium conditioned by
NRVMs expressing the T71A mutant, in which Thr71 of proBNP
was substituted with Ala, the proBNP/BNP ratio was signiﬁ-
cantly lower than in medium conditioned by NRVMs expressing
WT-proBNP. The T71A proBNP mutant was thus cleaved into
mature BNP to a signiﬁcantly greater extent than WT-proBNP
(Figure 5A). Furthermore, in medium from NRVMs expressing
the non-glyco mutant, in which all 7 glycosylation sites of
proBNP were replaced with Ala, the proBNP/BNP ratio was
markedly lower than in medium from cells expressing WT-
proBNP, and even from cells expressing the T71A mutant
(Figures 4B and 5A). This suggests that, in the absence of
glycosylation, nearly all proBNP is cleaved to mature BNP and
that glycosylation sites other than Thr71 are also involved in
regulating proBNP processing in cardiac myocytes.
To identify the other glycosylation sites that affect proBNP
processing, we measured human BNP and proBNP in medium
conditioned by NRVMs expressing a human proBNP mutant in
which only 1 of the glycosylation sites was preserved and the
other 6 were replaced with Ala (T71glyco, T58glyco, S53glyco,
T48glyco, S44glyco, S37glyco, and T36glyco) (Figures 4B and
5B). As anticipated, the proBNP/BNP ratio was signiﬁcantly
higher in medium conditioned by NRVMs expressing T71glyco
than by NRVMs expressing the non-glyco mutant. Among the
other mutants tested, the proBNP/BNP ratio in medium
conditioned only by NRVMs expressing T48glyco was signif-
icantly higher than that conditioned by NRVMs expressing the



















































































































































































































Figure 2. Peripheral metabolism of prohormone for brain natriuretic peptide (proBNP) in patients with heart failure. A through C, Dot plots
with meansSEM showing plasma levels of BNP (A), proBNP (B), and estimated mature BNP (C) in a peripheral artery and vein in individual
patients with heart failure (n=25). *P<0.05 using paired t test. D, Relationship between the proBNP/BNP ratios in veins and arteries of individual
patients. Pearson’s correlation coefﬁcient (r) was used for the analysis. P<0.05 is considered signiﬁcant. E, Dot plot with meansSEM showing
proBNP/BNP ratios in a peripheral artery and vein in individual patients with heart failure (n=25). *P<0.05 using paired t test. F and G, Relative
levels of cyclic GMP (cGMP) in neonatal rat ventricular myocytes (NRVMs) (F) or cardiac ﬁbroblasts (G) left untreated (control) or treated for
20 minutes with 108 mol/L of mature BNP, glycosylated proBNP (Glyco-proBNP), or nonglycosylated proBNP (Nonglyco-proBNP) (n=8 each
group). Relative cGMP levels in control NRVMs were assigned a value of 1.0. Data are shown as meansSEM. *P<0.05 using 1-way ANOVA with
post hoc Fisher’s test. H, Venous plasma cGMP levels-to-logBNPAO ratios (plasma cGMP/logBNPAO) in heart failure patients with high (n=27) or
low BNP (n=26). Data are shown as dot plots with meansSEM. *P<0.05 using unpaired t test.
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glycosylation sites, Thr71 and Thr48, are important for the
processing of proBNP in ventricular myocytes. We further
found that the proBNP/BNP ratio in medium conditioned by
NRVMs expressing T48/T71glyco was signiﬁcantly higher
than in medium conditioned by NRVMs expressing either
T48glyco or T71glyco alone, though the ratio was still lower
than in medium conditioned by NRVMs expressing WT-proBNP
(Figures 4B and 5C). The S53/T71glyco mutant showed no
additive effects on the proBNP/BNP ratio in medium condi-
tioned by NRVMs expressing T71glyco (Figure 5C). Con-
versely, the proBNP/BNP ratio in medium conditioned by
NRVMs expressing either the T71A or T48A mutant was
signiﬁcantly lower than in medium conditioned by NRVMs
expressing WT-proBNP (Figure 5D). Furthermore, the
proBNP/BNP ratio in medium conditioned by NRVMs express-
ing the T48A/T71A mutant was markedly lower than in
medium conditioned by NRVMs expressing either the T71A or
T48A mutant and was nearly identical to the ratio in medium
conditioned by NRVMs expressing the non-glyco mutant
(Figure 5D). Apparently glycosylation of both Thr71 and Thr48
is necessary to fully inhibit cleavage of proBNP. These results
demonstrate that Thr48 and Thr71 act cooperatively to play
an essential role in the processing and secretion of human
proBNP in cardiac myocytes.
As with cardiac myocytes, the proBNP/BNP ratio was
signiﬁcantly lower in medium conditioned by cardiac ﬁbrob-
lasts expressing either the T71A or T48A mutant than WT-
proBNP (Figure 5E). Thus, the machinery involved in the
glycosylation-dependent regulation of proBNP processing is
conserved, at least in part, between cardiac ventricular
myocytes and ﬁbroblasts. This is consistent with our earlier
ﬁnding that the ubiquitously expressed proteolytic enzyme
furin contributes to the processing of proBNP.16
To further conﬁrm that Thr48 and Thr71 are glycosylated in
proBNP, we used gel-ﬁltration in combination with an
immunochemiluminescent technique to compare the molec-
ular sizes of proBNP and mature BNP in medium conditioned
by NRVMs expressing WT-proBNP or the T71A, T71 glyco or
non-glyco mutant.7 The peak proBNP immunoreactivity in
medium conditioned by NRVMs expressing T71A was shifted
slightly rightward as compared to the WT-proBNP peak
(Figure 6A and 6B), which means T71A is smaller in size. In
addition, the amplitude of the proBNP immunoreactivity peak
relative to the mature BNP peak in medium conditioned by
NRVMs expressing T71A is markedly smaller than in medium
conditioned by NRVMs expressing WT-proBNP, which is
consistent with T71A being more easily cleaved to form
mature BNP than WT-proBNP (Figure 6A and 6B). In addition,
the proBNP immunoreactivity peaks for T71glyco and non-
glyco were shifted farther rightward than those for T71A and
WT-proBNP, as would be expected (Figure 6A through 6E).
Essentially the same results were obtained for comparisons
among WT-proBNP and the T48A, T48glyco, and non-glyco
mutants (Figure 6F through 6J).
GALNT1/2 Impair the Processing of proBNP in
Cardiac Myocytes
The N-acetylgalactosamine (GalNAc)-transferase (GALNT)














































































































Figure 3. Prohormone for brain natriuretic peptide (proBNP)/BNP ratios in conditioned medium of neonatal rat ventricular myocytes (NRVMs)
expressing human proBNP and human iPS-derived cardiac myocytes (iPS-CM). A through C, BNP levels (A), proBNP levels (B), and proBNP/BNP
ratios (C) in medium conditioned by NRVMs expressing human wild-type proBNP (WT-proBNP) in each experiment (n=23). D, ProBNP/BNP ratios
in medium conditioned by human iPS-derived cardiomyocytes (hiPS CM) and NRVMs. Data are shown as dot plots with meansSEM (n=4 each).
E through G, BNP levels (E), proBNP levels (F), and proBNP/BNP ratios (G) in medium conditioned by human iPS-CM in each experiment (n=14).
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Pig MGPRMALPR-VLLLLFLHLLLLGCRSY PLGGAGLASEL - - 
Rat MDLQKVLPQMILLLLFLNLSPLGGHSHPLGSPSQSPEQ - - 
Mouse MDLLKVLSQMILFLL FLYLSPLGGHSYPLGSPSQSPEQ - - 
Human SGL Q EQRNHLQGKLS ELQVEQTSLEPLQESPRP TGVWKSR 
Pig PGI Q ELL DRLRDRVS ELQAERTDLEPLRQDRGLT EAWEAR 
Rat STMQ KL LELI REKSE EM - - - - -AQRQLSKDQGP T - - - - - K  
Mouse FKMQ KLL ELI REKSEE M - - - - -AQRQLLKDQGLT
Human EVATEGIRGHRKMVLYTLRAPRSPKMVQGSG CFGRKMDRI
Pig EAAPTGVLGPRSS I FQVLRG IRSPKTMRDS GCFGR DRI 
Rat ELLKR RSQ-DSAFR I QERLRNSKMAHSSS CFGQ IRD
Mouse EHPKRVLR SQ-GSTLRVQQRPQNSKVTH I S S CFGH IRD
SSS SGLGCKVLRRH 
Pig GSL S GLGCNVLRRY 
Rat GAVS RLGCDGLRLF 
Mouse GSV S RLGCNALKLL 
- - - - - K  
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Figure 4. Mutation in glycosylation sites in the N-terminal region of prohormone for brain natriuretic
peptide (proBNP).A,Comparisonof theaminoacidsequencesofpre-proBNPfromhuman,pig, rat,andmouse.
Amino acids with a solid line circle are potentially glycosylated residues in human proBNP. Note that Thr48 is
conservedamong the4species (dashed line circle). B, Schema forwild-type (WT)-proBNPandvariousproBNP
mutants used in this study. T71A:mutant in which threonine (Thr) 71 is substituted with alanine (Ala). T48A/
T71A:mutant inwhichThr71andThr48aresubstitutedwithAla.Non-glyco:mutant inwhichall7glycosylation
sites are substitutedwith Ala. T71-glyco: mutant in which all glycosylation sites except Thr71 are substituted
withAla. T48/T71-glyco:mutant inwhich the5glycosylationsitesother thanThr71andThr48aresubstituted
to Ala.
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the GalNAca1-O-Ser/Thr linkage in O-glycosylation. To deter-
mine which GALNTs are involved in the O-linked glycosylation
of proBNP in cardiac myocytes, we evaluated the effect of
knocking down each of the GALNTs reportedly expressed in
the heart (GALNT 1, 2, 7, 10, 11, 12, and 15) using the
corresponding siRNA24 (Figure 7A). Among these, only knock-
down of GALNT1 or 2 signiﬁcantly reduced the proBNP/BNP
ratio in medium conditioned by NRVMs expressing WT-
proBNP (Figure 7B). Knockdown of GALNT3 did not affect the
proBNP/BNP ratio in medium conditioned by NRVMs express-
ing WT-proBNP (Figure 7C and 7D). Furthermore, in medium
conditioned by NRVMs expressing T48A/T71A, knockdown of
GALNT1 or 2 did not affect the proBNP/BNP ratio (Figure 7E).
We hypothesized that a decrease in the processing
efﬁciency of proBNP accounts for the increased proportion
of proBNP secreted by failing ventricles. To test that idea, we
assessed the effect of hypertrophic stimuli on proBNP
processing efﬁciency. We evaluated proBNP and BNP levels
in medium conditioned by FCS- or endothelin-1 (ET-1)-treated
NRVMs expressing WT-proBNP or a non-glyco mutant
(Tables 3 and 4), and then calculated the proBNP/BNP ratio.
















































































































































































































Figure 5. Two glycosylation sites, Thr48 and Thr71, modulate the processing of prohormone for brain natriuretic peptide (proBNP) in cardiac
myocytes. A through D, ProBNP/BNP ratios in medium conditioned by neonatal rat ventricular myocytes expressing WT-proBNP or the indicated
proBNP mutants. Data are shown as dot plots with meansSEM (n=4 each in A through C; n=3 in D). *P<0.05 using 1-way ANOVA with post
hoc Fisher’s test. E, ProBNP/BNP ratios in medium conditioned by cardiac ﬁbroblasts expressing wild-type (WT)-proBNP or indicated proBNP
mutants. Data are shown as dot plots with meansSEM. *P<0.05 (n=3 each) using 1-way ANOVA with post hoc Fisher’s test. Non-glyco: mutant
proBNP in which all 7 glycosylation sites are substituted with alanine (Ala). T71-glyco: mutant proBNP in which all glycosylation sites except
threonine (Thr) 71 are substituted with Ala. T58-glyco: mutant proBNP in which all glycosylation sites except Thr58 are substituted with Ala.
S53-glyco: mutant proBNP in which all glycosylation sites except serine (Ser) 53 are substituted with Ala. T48-glyco: mutant proBNP in which all
glycosylation sites except Thr48 are substituted with Ala. S44-glyco: mutant proBNP in which all glycosylation sites except Ser44 are
substituted with Ala. S37-glyco: mutant proBNP in which all glycosylation sites except Ser37 are substituted with Ala. T36-glyco: mutant proBNP
in which all glycosylation sites except Thr36 are substituted with Ala. T48/T71-glyco: mutant proBNP in which the 5 glycosylation sites other
than Thr71 and Thr48 are substituted to Ala. S53/T71-glyco: mutant proBNP in which the 5 glycosylation sites other than Thr71 and Ser53 are
substituted to Ala. T71A: mutant proBNP in which Thr71 is substituted with Ala. T48A: mutant proBNP in which in which Thr48 is substituted
with Ala. T48A/T71A: mutant proBNP in which Thr71 and Thr48 are substituted with Ala.
DOI: 10.1161/JAHA.116.003601 Journal of the American Heart Association 11



































proBNP mature BNP proBNP mature BNP
9282 037252 624222 32129181 027151 614121 311198 0175 642 31
WT
9282 037252 624222 32129181 027151 614121 311198 0175 642 31
9282 037252 624222 32129181 027151 614121 311198 0175 642 31
9282 037252 624222 32129181 027151 614121 311198 0175 642 31
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Figure 6. Gel ﬁltration analysis reveals glycosylation of human pro brain natriuretic peptide (proBNP). A
through J,Molecular sizes of humanproBNP inmediumconditionedbyneonatal rat ventricularmyocytes (NRVMs)
expressing wild-type (WT)-proBNP or the indicated proBNP mutants were determined by gel ﬁltration analysis. A
through D, Molecular sizes of human proBNP andmature BNP in medium conditioned by NRVMs expressing WT-
proBNP and T71A, T71glyco, or non-glyco mutant. E, Enlarged view of the peak proBNP immunoreactivity in
medium conditioned by NRVMs expressing WT-proBNP and T71A, T71glyco, or non-glyco mutant. F through I,
Molecular sizes of human proBNP andmature BNP inmedium conditioned byNRVMs expressingWT-proBNP, and
T48A, T48glyco, or non-glyco mutant. J, Enlarged view of the peak proBNP immunoreactivity in medium
conditioned by NRVMs expressingWT-proBNP and T48A, T48glyco, or non-glycomutant. Fractionswere assayed
using the conventional BNP assay system. The ﬁrst peak shows proBNP, and the second shows mature BNP.
Dotted lines and dashed lines indicate the immunoreactivity peaks forWT-proBNP and non-glycomutant proBNP,
respectively. Non-glyco: mutant proBNP in which all 7 glycosylation sites are substituted with alanine (Ala). T71-
glyco: mutant proBNP in which all glycosylation sites except threonine (Thr) 71 are substituted with Ala. T48-
glyco:mutant proBNP inwhich all glycosylation sites except Thr48 are substitutedwith Ala. T71A:mutant proBNP
in which Thr71 is substituted with Ala. T48A: mutant proBNP in which Thr48 is substituted with Ala.
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medium conditioned by NRVMs expressing WT-proBNP, but
had no effect on the ratios in medium conditioned by NRVMs
expressing the non-glyco mutant (Figure 7F and Table 3). ET-
1, which is well known to induce hypertrophic responses, had
a similar effect (Figure 7G and Table 4). These results
strongly suggest that pathological hypertrophic signaling-
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Figure 7. GALNT1 and 2 suppress prohormone for brain natriuretic peptide (proBNP) processing in cardiac myocytes. A, mRNA expression of
indicated N-acetylgalactosamine (GalNAc)-transferase (GALNT) genes in neonatal rat ventricular myocytes (NRVMs) transfected with the
corresponding siRNAs. The mRNA levels in NRVMs with control oligo were assigned a value of 1.0 (n=3 in each group). Data are shown as
meansSEM. *P<0.05 vs control, using unpaired t tests. B, proBNP/BNP ratios in medium conditioned by NRVMs expressing WT-proBNP and
transfected with siRNA targeting the corresponding GALNT (n=4 each). *P<0.05 using 1-way ANOVA with post hoc Fisher’s test. C, mRNA
expression of GALNT3 gene in NRVMs transfected with the siRNA for GALNT3. GALNT3 mRNA levels in NRVMs with control oligo were assigned
a value of 1.0 (n=3 in each group). Data are shown as meansSEM. *P<0.05 vs control, using unpaired t tests. D, proBNP/BNP ratios in
medium conditioned by NRVMs expressing WT-proBNP and transfected with siRNA targeting GALNT3 (n=4 each). N.S.: not signiﬁcant using 1-
way ANOVA with post hoc Fisher’s test. E, proBNP/BNP ratios in medium conditioned by NRVMs expressing T48A/T71A mutant and
transfected with GALNT1 or 2 siRNA (n=4 each). T48A/T71A mutant: mutant proBNP in which Thr71 and Thr48 are substituted with Ala. F and
G, proBNP/BNP ratios in medium conditioned by NRVMs expressing WT-proBNP or non-glyco and stimulated with the indicated concentrations
of fetal calf serum (FCS) (n=4 each) (F) or 59108 mol/L of endothelin-1 (ET-1) (n=8 each in WT-proBNP and 4 each in non-glyco) (G). *P<0.05
using 2-way ANOVA with post hoc Fisher’s test. In E–G, data are shown as dot plots with meansSEM. H and I, GALNT1/2 expression in NRVMs
treated with 10% FCS. Representative Western blots (H) and relative protein levels (I) are shown. Data are the meansSEM. The relative protein
levels in untreated NRVMs (control) were assigned as 1.0. *P<0.05 vs control, using unpaired t test (n=6 each).
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induced alterations in the glycosylation status of the proBNP
N-terminal region are responsible for the increased proportion
of proBNP secretion by failing hearts. Consistent with this
ﬁnding, FCS signiﬁcantly increased the levels of GALNT1/2
proteins in NRVMs (Figure 7H and 7I).
The microRNA-30 Family Promotes proBNP
Processing by Suppressing GALNT1/2
Expression in Cardiac Myocytes
We next sought to address the molecular mechanism by
which GALNT1/2 expression is increased in response to
hypertrophic stimulation. Expression levels of GALNT1/2
mRNA in NRVMs were signiﬁcantly increased by fetal calf
serum, but the increase in their transcript levels appears
somewhat modest compared to the increase in their protein
levels (Figure 8A). We identiﬁed a conserved target site for
miR-30 family members (miR-30a, b, c, d, and e) in the 30-
untranslated region (UTR) of both the GALNT1 and GALNT2
genes (Figure 8B). Although they are ubiquitously expressed,
miR-30s are among the most strongly expressed microRNAs
in cardiac myocytes.25 However, miR-30 expression in NRVMs
was signiﬁcantly reduced by FCS (Figure 8C). Overexpression
of a miR-30c mimic signiﬁcantly reduced endogenous levels of
GALNT1 and GALNT2 protein (Figure 9A and 9B), whereas
overexpression of a miR-30 inhibitor increased their protein
levels in NRVMs (Figure 9C and 9D). The miR-30c mimic also
signiﬁcantly reduced the activity of a luciferase reporter linked
to the 30-UTR of GALNT1/2, and a mutation in the predicted
miR-30 target site in the 30-UTR prevented that repression
(Figure 9E and 9F). All of these results indicate that reduced
expression of miR-30 family members caused by FCS led to
increases in GALNT1/2 expression in NRVMs. Furthermore,
the miR-30c mimic signiﬁcantly reduced the proBNP/BNP
ratio in medium conditioned by NRVMs expressing WT-
proBNP (Figure 9G). As was observed with NRVMs expressing
WT-proBNP, FCS dose-dependently increased the proBNP/
BNP ratio in medium conditioned by human iPS-CM (Fig-














































Table 3. ProBNP, BNP, and proBNP/BNP Ratio in Medium
Conditioned by FCS-Treated NRVMs Expressing WT-proBNP or
Non-Glyco Mutant
FCS 0.1% FCS 1% FCS 10%
WT-proBNP
BNP, pmol/L 184.24.2 289.26.5 360.33.7
proBNP, pmol/L 43.92.9 79.52.5 122.93.5
proBNP/BNP 0.2370.01 0.2750.0 0.3410.0
Non-glyco
BNP, pmol/L 264.99.6 123.419.4 185.029.8
proBNP, pmol/L 9.91.6 3.40.72 7.91.8
proBNP/BNP 0.0370.0 0.0270.0 0.0400.0
BNP indicates brain natriuretic peptide; FCS, fetal calf serum; non-glyco, non-glyco
mutant of proBNP; NRVMs, neonatal rat ventricular myocytes; proBNP, prohormone for
brain natriuretic peptide; WT-proBNP, wild-type proBNP.
Table 4. ProBNP, BNP, and proBNP/BNP Ratio in Medium




BNP, pmol/L 184.23.9 222.515.2
proBNP, pmol/L 43.92.7 63.05.4
proBNP/BNP 0.2390.01 0.2810.01
Non-glyco
BNP, pmol/L 157.520.9 120.624.2
proBNP, pmol/L 5.70.9 4.250.6
proBNP/BNP 0.0380.04 0.0350.01
BNP indicates brain natriuretic peptide; ET-1, endothelin-1; non-glyco, non-glyco mutant
of proBNP; NRVMs, neonatal rat ventricular myocytes; proBNP, prohormone for brain
natriuretic peptide; WT-proBNP, wild-type proBNP.
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signiﬁcantly reduced the proBNP/BNP ratio in their condi-
tioned medium (Figure 10B and 10C). Moreover, overexpres-
sion of the miR-30c mimic in iPS-CMs signiﬁcantly reduced
GALNT1/2 levels (Figure 10D and 10E) and the proBNP/BNP
ratio in the conditioned medium (Figure 10F).
In vivo administration of the miR-30c inhibitor to mice
signiﬁcantly increased cardiac levels of GALNT1/2 (Fig-
ure 10G and 10H). In addition, miR-30 expression was
signiﬁcantly lower and GALNT1/2 levels were signiﬁcantly
higher in the failing hearts of DS rats fed a HS diet than in the
control hearts of DS rats fed a LS diet (Figure 11A through
11C and Tables 5, 6).18
These results support our ﬁndings that decreased expres-
sion of miR-30s contributes to the increase in GALNT1 and 2
expression in failing hearts, which reduces the efﬁciency of
proBNP processing and, in turn, increased secretion of
inactive proBNP (Figure 11D).
Discussion
We were recently able to produce a highly sensitive and
accurate immunoassay system selective for human proBNP.7
Our system includes a capture antibody that is the same as
the one used in the conventional BNP assay system and
recognizes an epitope in the C-terminal regions of proBNP and
mature BNP, and a signal antibody that recognizes an epitope
in the N-terminal portion of proBNP. Although the epitopes of

































































































































































Figure 8. A conserved target site for miR-30 family members in the 30-untranslated region (UTR) of both the GALNT1 and GALNT2 genes. A,
Relative expression levels of GALNT1 and 2 mRNA in neonatal rat ventricular myocytes (NRVMs) treated with 10% fetal calf serum (FCS) for the
indicated times. Relative mRNA levels were determined by normalization to the level of GAPDH mRNA. Data are shown as meansSEM. The
relative mRNA levels in untreated NRVMs were assigned a value of 1.0. *P<0.05 using unpaired t tests. B, Schema of the GALNT1/2 genes.
30UTR: 30 untranslated region. C, Quantitative real-time polymerase chain reaction analysis of the miR-30 family in NRVMs with 10% FCS
stimulation (n=12 each). *P<0.05 vs NRVMs without FCS, using unpaired t test.
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Figure 9. The microRNA-30 family regulates GALNT1/2 expression in cardiac myocytes. A through D, Expression of GALNT1/2
protein in neonatal rat ventricular myocytes (NRVMs) transfected with a miR-30c mimic (A and B) or a miR-30 inhibitor (C and D).
Representative Western blots (A and C) and relative protein levels (n=6 per group) (B and D) are shown. The relative protein levels in
untreated NRVMs (control) were assigned a value of 1.0. *P<0.05 vs control, using unpaired t test. E and F, Schema of wild-type (WT)
and mut GALNT1 30-untranslated region (30UTR)-luc (upper panel of E) and WT and mut GALNT2 30UTR-luc (upper panel of F), and
relative luciferase activity of WT or mut GALNT1 30UTR-luc (lower panel of E) and WT or mut GALNT2 30UTR-luc (lower panel of F) with or
without the miR-30mimic. The relative luciferase activity of WT andmut GALNT1/2 30UTR-luc without the miR-30mimic was assigned a
value of 1.0. *P<0.05 using unpaired t test within WT or mut GALNT1/2 30UTR-luc group (n=8 each). Data are shown in meansSEM. G,
prohormone for brain natriuretic peptide (proBNP)/BNP ratios in medium conditioned by NRVMs expressing WT-proBNP and
transfected with a miR-30c mimic (n=7 each). Data are shown as dot plots with meansSEM. *P<0.05 using unpaired t test.
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Figure 10. Mir-30-GALNT1/2 axis in human iPS-cardiomyocytes (CM) and mouse in vivo hearts. A, prohormone for brain
natriuretic peptide (proBNP)/BNP ratios in medium conditioned by human iPS-CM stimulated with the indicated concentrations of
fetal calf serum (FCS) (n=4 each). *P<0.05 vs 0.1% FCS using 1-way ANOVA with post hoc Fisher’s test. Data are shown as dot plots
with meansSEM. B, mRNA expression of indicated GALNT genes in human iPS-CM transfected with the corresponding siRNAs. The
mRNA levels in iPS-CM with control oligo were assigned a value of 1.0 (n=3 in each group). Data are shown as meansSEM. *P<0.05
vs control, using unpaired t tests. C, proBNP/BNP ratios in medium conditioned by human IPS-CM transfected with the
corresponding siRNAs (n=4 each). *P<0.05 vs control oligo using 1-way ANOVA with post hoc Fisher’s test. Data are shown as dot
plots with meansSEM. D and E, Expression of GALNT1/2 protein in human iPS-CM transfected with a miR-30c mimic.
Representative Western blots (D) and relative protein levels (n=6 per group) (E) are shown. The relative protein levels in iPS-CM
treated with control oligo (control) were assigned a value of 1.0. *P<0.05 vs control, using unpaired t test. F, proBNP/BNP ratios in
medium conditioned by human iPS-CM transfected with a miR-30c mimic (n=4 each). Data are shown as dot plots with meansSEM.
*P<0.05 using unpaired t test. G and H, Cardiac expression of GALNT1/2 protein in mice administered with a miR-30c inhibitor.
Representative Western blots (G) and relative protein levels (n=5 per group) (H) are shown. We conﬁrmed that in mice treated with
rmiR-30c inhibitor the cardiac miR-30c expression levels were reduced to 4% of that in mice treated with negative control. The
relative protein levels in mice treated with control scrambled oligo (control) were assigned a value of 1.0. *P<0.05 vs control, using
unpaired t test.
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conventional one, their afﬁnities for their epitopes are
similar.7 Consequently, by simultaneously using these 2
assay systems, we are able to calculate the proBNP/BNP
ratio as an index of the proportion of proBNP among the
immunoreactive BNP forms, which consists of proBNP and
mature BNP. In this study, we showed that both the cardiac
production of proBNP and the proportion of proBNP among
secreted BNP forms increase with increases in the severity of
heart failure in humans. Examination of peripheral metabolism
revealed our results to be consistent with earlier studies
showing that proBNP has much less ability to stimulate cGMP
production than mature BNP.10 It is therefore likely that the
increased proportion of proBNP secreted from the heart
attenuates the increase in cGMP levels, despite high plasma
BNP levels in patients with severe heart failure.11,26,27
A recent study raised the possibility that proBNP is
processed to mature BNP in the circulation.28 Those inves-
tigators incubated histidine-tagged recombinant nonglycosy-
lated-proBNP with venous serum and/or plasma collected
from healthy subjects and used Western blot analysis to
assess processing. In addition, Vodovar et al observed venous
furin-like enzyme activity that was well correlated with NT-
proBNP/total proBNP ratio and proposed that there may be
peripheral processing of proBNP to mature BNP in acute heart
failure patients.29 By contrast, when we sampled venous
blood from the superior vena cava or femoral vein and arterial
blood from the cubital or femoral artery, respectively, of
patients admitted for heart failure, we found that proBNP
concentrations did not differ between a peripheral vein and
artery in our population. This makes it unlikely that proBNP is
metabolized in peripheral tissues or blood in these patients.
The discrepancy between our results and those earlier
ﬁndings may be explained in part by the differences between
the in vivo and in vitro settings, between glycosylated proBNP
and nonglycosylated proBNP, and/or between the clinical
status of the heart failure patients.
We also clearly showed for the ﬁrst time that, among
human proBNP’s 7 potential O-glycosylation sites, Thr71 and
Thr48 act cooperatively to inhibit proBNP processing and
promote proBNP secretion by ventricular myocytes. Never-
theless, the proBNP secretion from myocytes expressing the
T48/71glyco mutant, in which only T48 and T71 could be
glycosylated, did not recapitulate the proBNP production from
myocytes expressing WT-proBNP, suggesting that O-glycan
attachments to the other 5 sites indirectly affect the
processing of proBNP, probably by supporting the glycans
attached to Thr48 and Thr71. Recent evidence indicates that
GALNT-mediated O-glycosylation signiﬁcantly affects protein
processing, which can in turn modify pathophysiological
processes.30 For example, secretion of ﬁbroblast growth
factor-23 requires GALNT3-mediated O-glycosylation, which
inhibits processing of ﬁbroblast growth factor-23 into inacti-
vated fragments.31,32 In this study, we demonstrate that
stress-induced increases in GALNT1/2 expression and the O-
glycosylation they catalyze inhibits proBNP processing, lead-
ing to a higher proportion of inactive proBNP secretion under
pathological conditions in the heart (Figure 11D). Though
there is a report that GALNT3 can direct O-glycosylation at
Thr71 in the synthetic proBNP peptide in vitro,33 GALNT3
expression is reported to be barely detectable in the
heart.24,30 Furthermore, we conﬁrmed that GALNT3 siRNA
did not affect proBNP/BNP ratio in medium conditioned by
NRVMs expressing WT-proBNP (Figure 7C and 7D).
The miR-30 family is ubiquitously expressed, but they are
among the most highly expressed microRNAs in cardiac
myocytes,25 and recent in vitro observations revealed their
involvement in the regulation of various cellular processes.34
Cardiac expression of miR-30s reportedly decreases substan-
tially over the course of pathological cardiac remodeling in
both rodents and humans.25 Consistent with that report, we
found in the present study that levels of all members of the
miR-30 family are signiﬁcantly reduced in failing rat hearts
and in hypertrophic NRVMs. It was recently reported that miR-
30b and d negatively regulate GALNT1 and 7 expression in
melanoma cells, and that silencing GALNT7 mediates miR-
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consistent with our ﬁndings that miR-30-mediated suppres-
sion of GALNT1/2 expression decreases proBNP glycosyla-
tion and its secretion from cardiac myocytes.
Even relatively small changes in proBNP/BNP ratios, if it
lasts for a long time, can sufﬁciently cause the decrease in the
sum of cGMP production, thereby leading to the development
or progression of cardiac diseases, because the potential of
proBNP to produce cGMP is much weaker than that of mature
BNP. In a recent clinical study, LCZ696, a neprilysin inhibitor
combined with angiotensin receptor antagonist, signiﬁcantly
repressed the cardiovascular events compared to enalapril,
even though LCZ696 only slightly increased the plasma levels
of BNP, demonstrating clearly that even small alterations in
plasma levels of functional BNP can sufﬁciently affect the
pathophysiological process of cardiovascular diseases.36
Thus, the miR-30-GALNT pathway, which modulates the
production and secretion of biologically active mature BNP,
can be a novel therapeutic target for the treatment of heart
failure. Further studies are needed to clarify the therapeutic
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Figure 11. Expression of miR-30 family members is reduced and expression of GALNT 1/2 proteins is elevated in rat failing ventricles. A,
Quantitative real-time polymerase chain reaction for miR-30 family members in ventricles from the healthy hearts of Dahl salt-sensitive (DS) rats
fed a low-salt diet (cont) (n=17) and the failing hearts of DS rats fed a high-salt diet (CHF) (n=14). Rats in all groups were 17 weeks of age. Data
are shown as meansSEM. The relative levels of miR-30s in normal hearts (cont) were assigned a value of 1.0. B and C, Expression of GALNT1/
2 protein in ventricles from the normal hearts (cont) and the failing hearts (CHF) of DS rats. Representative Western blots (B) and relative protein
levels (C) (n=6 per group) are shown. The relative protein levels in normal hearts (control) were assigned a value of 1.0. *P<0.05 vs cont using
unpaired t test. D, Proposed model of the miR-30s-GALNT axis-dependent regulation of glycosylation and secretion of unprocessed human
prohormone for brain natriuretic peptide (proBNP). Under pathological conditions in the heart, BNP gene expression is increased, resulting in
increased translation of proBNP. At the same time, reduction in miR-30 expression leads to increased GALNT1/2 expression, thereby increasing
human proBNP glycosylation and decreasing the efﬁciency of proBNP processing to bioactive mature BNP. The resultant increase in the
proportion of biologically inactive proBNP that is secreted attenuates the compensatory actions of BNP, despite its high plasma levels during the
progression of heart failure.
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Our study has some limitations. First, the number of the
samples in the human study 2 is relatively small. Second, we
did not have patients’ myocardium samples that enable us to
evaluate cardiac miR-30 or GALNT1/2 expression levels in the
patients enrolled in this study. Future studies examining the
association between cardiac levels of miR-30 or GALNT1/2
and plasma proBNP/BNP ratios in human are needed.
In summary, our study sheds light on a novel molecular
pathway leading to impairment of compensatory BNP actions
that is mediated by a miR-30-GALNT1/2 axis during the
development of heart failure in humans. Further investigation
of the roles played by this pathway in the progression of heart
failure could serve as the basis for novel therapeutic
approaches to the prevention and treatment of chronic heart
failure.
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